 | • レポートコード：MRC2303G109 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療機器 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の抗バイオフィルム創傷ドレッシング市場規模が、予測期間中、CAGR 9.5％で増加すると推測されています。本書では、抗バイオフィルム創傷ドレッシングの世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、メカニズム別（物理的、化学的、生物学的）分析、創傷種類別（慢性創傷、急性創傷）分析、エンドユーザー別（病院・診療所、手術センター、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Convatec Inc.、Smith+Nephew、URGO、Coloplast Corp.、3M、B. Braun SE、Mölnlycke Health Care AB、Imbed Biosciences、Medline Industries, LP、Integra LifeSciencesなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の抗バイオフィルム創傷ドレッシング市場規模：メカニズム別 - 物理的抗バイオフィルム創傷ドレッシングの市場規模 - 化学的抗バイオフィルム創傷ドレッシングの市場規模 - 生物学的抗バイオフィルム創傷ドレッシングの市場規模 ・世界の抗バイオフィルム創傷ドレッシング市場規模：創傷種類別 - 慢性創傷における市場規模 - 慢性創傷における市場規模 ・世界の抗バイオフィルム創傷ドレッシング市場規模：エンドユーザー別 - 病院・診療所における市場規模 - 手術センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の抗バイオフィルム創傷ドレッシング市場規模：地域別 - 北米の抗バイオフィルム創傷ドレッシング市場規模 アメリカの抗バイオフィルム創傷ドレッシング市場規模 カナダの抗バイオフィルム創傷ドレッシング市場規模 メキシコの抗バイオフィルム創傷ドレッシング市場規模 … - ヨーロッパの抗バイオフィルム創傷ドレッシング市場規模 ドイツの抗バイオフィルム創傷ドレッシング市場規模 イギリスの抗バイオフィルム創傷ドレッシング市場規模 フランスの抗バイオフィルム創傷ドレッシング市場規模 … - アジア太平洋の抗バイオフィルム創傷ドレッシング市場規模 中国の抗バイオフィルム創傷ドレッシング市場規模 日本の抗バイオフィルム創傷ドレッシング市場規模 インドの抗バイオフィルム創傷ドレッシング市場規模 … - 南米/中東の抗バイオフィルム創傷ドレッシング市場規模 ブラジルの抗バイオフィルム創傷ドレッシング市場規模 アルゼンチンの抗バイオフィルム創傷ドレッシング市場規模 サウジアラビアの抗バイオフィルム創傷ドレッシング市場規模 ・競争状況 ・市場機会・将来動向 |
The anti-biofilm wound dressing market is expected to register a CAGR of 9.5% over the forecast period.
Key Highlights
- The COVID-19 pandemic had a significant impact on the anti-biofilm wound dressing market as the majority of the healthcare facilities were occupied with the management of COVID-19 patients. The elective procedures were postponed during the initial phase of the lockdown, which significantly impacted wound care management. The number of patient visits reported a substantial decline during the lockdown period. According to a study conducted by Ludwig Maximilian University, Munich, Germany, around 23% of patients suffering from chronic wounds were not able to visit physicians due to the pandemic. Moreover, around 10% of respondents avoided doctor visits as a precaution.
- The increased use of telehealth in the management of chronic and acute wounds was responsible for the strong recovery of the market. Various healthcare providers developed telehealth platforms in order to effectively manage patients suffering from acute and chronic wounds. For instance, in January 2021, Wound Pros Inc. developed a telehealth platform for communication between patients and professionals. The provider also invented an app named “RITA,” which helps in new diagnostic and wound measurement.
- The unhealed wounds caused by chronic diseases (such as diabetes, venous, or arterial disorders) show bacterial contamination film on the wound surface. The growing cases of chronic and acute wounds are expected to drive the growth of the market during the forecast period. According to the research published by National Center for Biotechnology Information in June 2022, the global prevalence of pressure ulcers is close to 12.8%, with hospital-acquired pressure injury (HAPI) accounting for 8.4% of patients.
- Moreover, the evolving healthcare infrastructure in developing countries across the globe, technological advancements in the field of wound management, and combined initiatives taken by key players and healthcare providers to increase awareness about wound care are also supporting the market’s growth. For instance, in February 2022, Asep Medical Holdings Inc. announced positive outcomes related to the Antibiofilm/Anti-inflammatory Peptide Technology developed with the help of the United States Army Medical Research and Materiel Command.
- These are the key factors expected to drive the demand for advanced wound dressing solutions, including anti-biofilm products, in the near future. However, high costs associated with wound care treatment, along with the scarcity of skilled professionals, are anticipated to impede the growth of the market.
Anti-Biofilm Wound Dressing Market Trends
Chemical Segment is Expected to Witness Significant Growth Over the Forecast Period
- The chemical anti-biofilm dressing segment is anticipated to register significant growth owing to the presence of key players in the segment with iodine and ionic silver-based products, along with the rising number of patients suffering from chronic diseases. Moreover, the introduction of innovative products by major players in this segment is also responsible for the significant share of chemical anti-biofilm dressing products in the market. For instance, in November 2020, Sanara MedTech launched BIAKŌS Antimicrobial Skin and Wound Cleanser in the market. The clinical studies revealed that after the application of the product, it disrupted biofilm microbes within 72 hours.
- The increasing prevalence of chronic wounds (like venous leg ulcers, pressure ulcers, and diabetic foot ulcers) due to a surge in the prevalence of medical conditions such as diabetes is also augmenting the growth of the segment. According to the International Diabetes Federation, in 2021, more than 537 million adults were suffering from diabetes across the world. The number is likely to surpass 640 million by the end of 2030. According to the article published in Healogics, around 7 million Americans are living with a chronic wound, and it indicated an increase of 50% in amputations during the pandemic.
- Therefore, the chemical anti-biofilm dressing segment is expected to witness significant growth over the forecast period due to the introduction of innovative products and the increasing prevalence of chronic wounds.
North America is Expected to Dominate the Anti-Biofilm Wound Dressing Market
- North America is expected to dominate the market owing to factors such as the easy availability of technologically advanced products and the increasing number of wound care clinics in the region. An increase in the usage of advanced products in the healthcare facilities, such as hospitals and ambulatory surgical centers in the United States, is among the key factors which contribute to the growth of the market studied in North America. The presence of key market players such as 3M, B. Braun SE, Convatec Inc., Smith+Nephew, and Coloplast Corp in the region, along with favorable reimbursement policies, are also anticipated to drive the market.
- Increasing expenditure on the management of wounds, including pressure ulcers, is also driving the growth of the market. According to the article published by the Agency for Healthcare Research and Quality, every year, around 2.5 million patients suffer from pressure ulcers, and the cost of individual patient care ranges from USD 20,900-151,700 per patient in the United States.
- The well-developed infrastructure in the region and the increasing number of road accidents in the United States are also propelling the growth of the market in the region. According to the National Highway Traffic Safety Administration, the number of road accidents is continuously increasing in the United States. Road accidents were responsible for more than 42,000 fatalities in 2021, which reflects a 10.5% increase as compared to 38,824 fatalities reported in 2020.
- Owing to the factors such as the presence of key market players, increasing expenditure on wound management, and increasing number of road accidents, the US anti-biofilm wound dressing market is anticipated to show significant growth in North America.
Anti-Biofilm Wound Dressing Market Competitor Analysis
The anti-biofilm wound dressing market is moderately fragmented in nature due to the presence of several companies operating globally and regionally.
The competitive landscape includes an analysis of a few international as well as local companies which hold large market shares and are well known, including Convatec Inc., Smith+Nephew, URGO, Coloplast Corp., 3M, B. Braun SE, Mölnlycke Health Care AB, Imbed Biosciences, Medline Industries LP, and Integra LifeSciences, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Wounds
4.2.2 Introduction of Innovative Products in Advanced Wound Care
4.2.3 Surge in the Number of Surgical Procedures
4.3 Market Restraints
4.3.1 High Product Cost Along with the Increasing Utilization of Substitutes
4.4 Industry Attractiveness – Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Mechanism
5.1.1 Physical
5.1.2 Chemical
5.1.3 Biological
5.2 By Wound Type
5.2.1 Chronic Wounds
5.2.1.1 Diabetic Foot Ulcers
5.2.1.2 Pressure Ulcers
5.2.1.3 Venous Leg Ulcers
5.2.1.4 Other Chronic Wounds
5.2.2 Acute Wounds
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Surgical Centers
5.3.3 Other End Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Convatec Inc.
6.1.2 Smith+Nephew
6.1.3 URGO
6.1.4 Coloplast Corp.
6.1.5 3M
6.1.6 B. Braun SE
6.1.7 Mölnlycke Health Care AB
6.1.8 Imbed Biosciences
6.1.9 Medline Industries, LP
6.1.10 Integra LifeSciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS